Revolution Medicines (NASDAQ:RVMD – Get Free Report) and Fennec Pharmaceuticals (NASDAQ:FENC – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Institutional & Insider Ownership
94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by insiders. Comparatively, 11.8% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent recommendations for Revolution Medicines and Fennec Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Revolution Medicines | 0 | 0 | 12 | 0 | 3.00 |
| Fennec Pharmaceuticals | 0 | 0 | 3 | 1 | 3.25 |
Profitability
This table compares Revolution Medicines and Fennec Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Revolution Medicines | N/A | -33.67% | -30.08% |
| Fennec Pharmaceuticals | -2.30% | -53.38% | -2.08% |
Volatility and Risk
Revolution Medicines has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.
Valuation & Earnings
This table compares Revolution Medicines and Fennec Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Revolution Medicines | $742,000.00 | 9,900.82 | -$436.37 million | ($4.00) | -9.86 |
| Fennec Pharmaceuticals | $47.54 million | 3.80 | -$16.05 million | ($0.06) | -109.17 |
Fennec Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Summary
Fennec Pharmaceuticals beats Revolution Medicines on 8 of the 15 factors compared between the two stocks.
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
